|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165256 |
The purpose of this study is to determine if wide excision (surgical removal) of the ductal carcinoma in situ of the breast (DCIS) alone is adequate therapy.
Condition | Intervention | Phase |
Duct Carcinoma in Situ of the Breast |
Procedure: Wide Excision of DCIS |
Phase II |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Cancer |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Wide Excision Alone for DCIS-Grades 1 and 2 |
Enrollment: | 200 |
Study Start Date: | May 1995 |
Estimated Study Completion Date: | July 2008 |
Primary Completion Date: | July 2002 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02115 | |||||
Dana-Farber Cancer Center | |||||
Boston, Massachusetts, United States, 02115 |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Massachusetts General Hospital |
Beth Israel Deaconess Medical Center |
Principal Investigator: | Julia Wong, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute/Brigham and Women's Hospital ( Julia Wong, MD ) |
Study ID Numbers: | 94-151 |
First Received: | September 9, 2005 |
Last Updated: | December 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00165256 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|